QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
OTCMKTS:ASPCF

Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis

$0.22
0.00 (0.00%)
(As of 07/21/2023)
Today's Range
$0.22
$0.22
50-Day Range
$0.22
$0.22
52-Week Range
$0.22
$8.16
Volume
N/A
Average Volume
1,500 shs
Market Capitalization
$1.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ASPCF stock logo

About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF)

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

ASPCF Stock Price History

ASPCF Stock News Headlines

New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Acerus Reports Third Quarter 2022 Financial Results
Acerus Announces Initiation of Strategic Review
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Acerus Announces Completion of Share Consolidation
Acerus Announces Share Consolidation
See More Headlines
Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ASPCF
CIK
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-33,820,000.00
Net Margins
-924.33%
Pretax Margin
-924.33%

Debt

Sales & Book Value

Annual Sales
$2.12 million
Book Value
($3.38) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.70 million
Optionable
Not Optionable
Beta
0.69
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Edward Gudaitis
    President, CEO & Non-Independent Director
  • Naveed Manzoor
    Chief Financial Officer
  • Christopher Sorli
    Chief Medical Officer
  • Philippe Savard
    Secretary, Senior Vice President & General Counsel
  • Chris Witty
    Investor Relations Contact

ASPCF Stock Analysis - Frequently Asked Questions

How have ASPCF shares performed in 2024?

Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2024. Since then, ASPCF shares have increased by 0.0% and is now trading at $0.22.
View the best growth stocks for 2024 here
.

When did Acerus Pharmaceuticals' stock split?

Acerus Pharmaceuticals shares reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ASPCF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners